LUND, Sweden, May 13, 2020 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia") today provides an update on the actions that
the company is taking in response to the coronavirus (COVID-19)
pandemic. During these challenging times, Immunovia remains focused
on the sales start of the first-to-market test for early diagnosis
of pancreatic cancer, IMMray™ PanCan-d.
Governor Baker of Massachusetts,
USA issued an extended Emergency Order to May 18th, 2020, resulting in the
further closure of certain workplaces and facilities to workers,
customers, and public, as well as the prohibition on gatherings of
more than 10 people (Extended Emergency Order Press Release). Due
to the extension of the Emergency Order, Immunovia's lab located in
Marlborough, Massachusetts will
remain closed at this time. As an effect of COVID-19, Immunovia is
now forced to revise the company's timeline and sales start date
for IMMray™ PanCan-d, now targeting Q4 2020. This decision factors
in the possibility of any further extensions by the Government of
Massachusetts to the beginning of
June.
As previously announced, Immunovia has put in place mitigations
that include moving activities within the company, which has
successfully minimized the impact of the initial Massachusetts' emergency order lockdown. As a
consequence of the new timeline, the ongoing Verification Study
will be completed in Q3 2020 and the Validation Study will be
completed in Q4 2020.
"I want to remind our staff and all our stakeholders that,
despite the global pandemic and these difficult times, we will
still be the first-to-market with a very accurate test for early
detection of pancreatic cancer. This fact has not changed," stated
Mats Grahn, CEO of Immunovia.
In conjunction, Immunovia will host a live call today at
16:30 CET with Mats Grahn, CEO, to further discuss COVID-19 and
IMMray™ PanCan-d launch preparations.
Participants will need to pre-register for the call via the
following link: Register Here
Once pre-registered, each participant will then receive a
personal user code to access the live call.
For the live call, please call in a few minutes in advance. To
attend, please dial-in at one of the numbers below and provide the
conference code 2514192 to the operator as well as your user
code obtained from pre-registration:
Conference Dial in numbers:
Sweden: +46-(0)-8-5051-0086
United States:
+1-646-843-4609
Austria: +43-(0)-1928-4054
Denmark: +45-3272-9274
Finland: +358-9-2319-5436
France: +33-(0)-4-2684-0314
Germany: +49-(0)-511
9361-2555
Netherlands:
+31-(0)-20-7948428
Norway: +47-2-156-3319
Spain: +34-91-787-0778
UK (Standard International Access): +44-(0)-20-3003-2701
Conference Code: 2514192
User Code: obtained from pre-registration (Register
Here)
Immunovia
Webcast: https://channel.royalcast.com/webcast/immunovia/20200513_1/
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
There will be an MP3-file available at Immunovia's webpage under
Investors/Audio-Gallery
(https://immunovia.com/investors/audio-gallery/) for those who want
to listen to the telephone conference afterwards. The file will be
available within two hours after the conference has ended.
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 16:00 CET on
May 13, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q4
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough,
Massachusetts, USA and Lund,
Sweden will provide laboratory testing services in two
accredited reference laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
Contact:
Immunovia AB
Medicon Village Scheelevägen 2 SE-223 81 Lund
+46-46-275-60-00
http://www.immunovia.com
info@immunovia.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-provides-third-update-during-covid-19-pandemic,c3110857
The following files are available for download:
https://mb.cision.com/Main/13121/3110857/1247137.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-provides-third-update-during-covid-19-pandemic-301058599.html
SOURCE Immunovia AB